Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556887 | 0.90 | CYP2D6 (0.48) | CYP2D6NPY5RALOX15CDK2 | |
| SCHEMBL21093187 | 0.88 | CYP2D6 (0.50) | CYP2D6ALOX15UBE2MDCUN1D1SMN1; SMN2 | |
| SCHEMBL16675917 | 0.87 | NPY5R (0.43) | CYP2D6NPY5RCDK2CCNA2CCNA1 | |
| SCHEMBL19135677 | 0.86 | CYP2D6 (0.57) | CYP2D6NPY5RALOX15CDK2CCNA2 | |
| SCHEMBL18556885 | 0.84 | CYP2D6 (0.49) | CYP2D6ALOX15SMN1; SMN2NPC1MAPT | |
| SCHEMBL16682121 | 0.83 | CYP2D6 (0.48) | CYP2D6ALOX15UBE2MDCUN1D1RAF1 | |
| SCHEMBL16812137 | 0.83 | CYP2D6 (0.48) | CYP2D6ALOX15 | |
| SCHEMBL16811839 | 0.81 | CYP2D6 (0.54) | CYP2D6ALOX15CDK2CCNA2CCNA1 | |
| SCHEMBL16860011 | 0.81 | CYP2D6 (0.54) | CYP2D6ALOX15CDK2CCNA2CCNA1 | |
| SCHEMBL16865709 | 0.81 | CYP2D6 (0.65) | CYP2D6ALOX15CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CYP2D6 3177/4885NPY5R 4621/4885ALOX15 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.